Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended		50 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Revenue
Product sales	$ 114	$ 73	$ 187
Revenue	114	73	187
Cost of goods sold	50	26	76
Gross profit	64	47	111
Operating expenses:
Research and development	1,084	1,403	3,444
General and administrative	1,015	2,232	3,708
Sales and marketing	25	30	55
Goodwill impairment loss		8,127	8,127
Operating expenses	2,124	11,792	15,334
Loss from operations before other income / (expense)	(2,060)	(11,745)	(15,223)
Other income/(expense):
Interest expense, net	(96)	(108)	(242)
Reversal for allowance of notes receivable from SyntheMed, Inc.		459
Reversal of a liability		124	124
Other income/(expense)	(96)	475	(118)
Net loss	$ (2,156)	$ (11,270)	$ (15,341)
Net loss per common share-basic and diluted	$ 0.00	$ (0.02)
Weighted average shares outstanding	667,162	526,105